Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors
Rhea-AI Summary
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has appointed John Farlinger to its Board of Directors, where he will also serve as Chair of the audit committee. Farlinger brings over 30 years of experience in telecom, operations, technology, and finance, currently serving as Assure Neuromonitoring's executive chairman and CEO. He is a Chartered Professional Accountant with a Bachelor of Commerce from Queen's University.
As part of the appointment, the company has granted 850,000 stock options, with 350,000 allocated to Farlinger and 500,000 to a strategic consultant. The options are exercisable at $0.15 per share for five years, vesting immediately with a four-month hold period until August 2, 2025, subject to TSX Venture Exchange approval.
Positive
- Appointment of experienced executive with 30+ years in telecom, operations, technology and finance
- Addition of qualified financial oversight with CPA joining as audit committee chair
Negative
- Dilutive effect of 850,000 new stock options at $0.15 per share
News Market Reaction
On the day this news was published, TDSGF gained 0.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee.
Mr. Farlinger is a veteran venture and private equity backed executive and entrepreneur, bringing more than 30 years of experience in telecom, operations, technology and finance. He currently serves as Assure Neuromonitoring's executive chairman and CEO. Mr. Farlinger is a Chartered Professional Accountant (CPA, CA) and graduated with a Bachelor of Commerce (Hons) from Queen's University.
"We are thrilled to welcome John to our board, and we look forward to working together," said Telo Genomics Executive Chairman, Guido Baechler, "His experience in strategic leadership and financing small cap growth companies is an excellent fit for the current stage of development of Telo Genomics."
Pursuant to the Company's stock option plan, the Company has granted 850,000 stock options with 350,000 stock options granted to Mr. Farlinger and 500,000 stock options granted to a strategic consultant to the Company. All stock options granted are exercisable at
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Guido Baechler
Executive Chairman
416-673-8487
info@telodx.com
MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247277
FAQ
What role will John Farlinger take at Telo Genomics (TDSGF)?
How many stock options did Telo Genomics (TDSGF) grant in April 2025?
What are the terms of TDSGF's April 2025 stock option grant?
What experience does John Farlinger bring to Telo Genomics (TDSGF)?
